2007 GOLD Report—LAMA/LABAs now recommended 1st-line for most patients.

DUAL BRONCHODILATION

COMPLEMENTARY BRONCHODILATION,

DOWN TO A SCIENCE

LAMA/LABAs provide a more comprehensive approach to bronchodilation through 2 mechanisms of actionLAMAs decrease bronchoconstriction, LABAs promote bronchodilation1,2

LAMA/LABAs provide a more comprehensive approach to bronchodilation through 2 mechanisms of action LAMA/LABAs provide a more comprehensive approach to bronchodilation through 2 mechanisms of action
LAMAs target M3 receptors, which are more concentrated in the proximal airways LAMAs target M3 receptors, which are more concentrated in the proximal airways
LABAs target β2 receptors located throughout the lungs LABAs target β2 receptors located throughout the lungs

*Initial treatment in Group B patients with severe breathlessness and in Group D patient.6

†Based on IMS Monthly NPA data reporting total prescriptions for LAMA, ICS/LAMA, LAMA/LABA, LABA, SABA, SAMA, SABA/SAMA for a 6-month time period ending January 2016 vs January 2017.

For illustrative purposes only.